Key Points
- Insider sale: Director J. Jefferson Smith sold 4,925 shares on Feb. 18 at an average of $3.84 for $18,912, trimming his stake by 3.88% to 121,926 shares valued at about $468,196.
- Stock performance: DTIL traded at $3.78 (down $0.15) with a market cap of $86.45M and 12-month range of $3.53–$8.82; its 50-day and 200-day moving averages are $4.14 and $5.01, respectively.
- Ratings and ownership: The stock has a MarketBeat consensus rating of "Hold" (one Buy, one Sell) and a stated consensus target of $60.00, while institutional investors own about 37.99% and several small institutional stakes were added recently.
Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) insider J. Jefferson Smith sold 4,925 shares of the business's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $3.84, for a total value of $18,912.00. Following the transaction, the insider directly owned 121,926 shares of the company's stock, valued at approximately $468,195.84. The trade was a 3.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.
J. Jefferson Smith also recently made the following trade(s):
- On Wednesday, January 21st, J. Jefferson Smith sold 10,200 shares of Precision BioSciences stock. The shares were sold at an average price of $4.03, for a total transaction of $41,106.00.
Precision BioSciences Price Performance
DTIL stock traded down $0.15 during trading on Friday, reaching $3.78. 38,118 shares of the company were exchanged, compared to its average volume of 219,939. The company has a market capitalization of $86.45 million, a price-to-earnings ratio of -0.45 and a beta of 1.31. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.45 and a quick ratio of 3.45. The company has a 50-day moving average of $4.14 and a two-hundred day moving average of $5.01. Precision BioSciences, Inc. has a twelve month low of $3.53 and a twelve month high of $8.82.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of DTIL. HBK Sorce Advisory LLC bought a new stake in shares of Precision BioSciences in the 4th quarter valued at about $38,000. Engineers Gate Manager LP bought a new position in shares of Precision BioSciences during the fourth quarter worth about $43,000. Occudo Quantitative Strategies LP acquired a new position in shares of Precision BioSciences in the fourth quarter worth approximately $52,000. Miller Financial Services LLC boosted its holdings in Precision BioSciences by 50.0% in the fourth quarter. Miller Financial Services LLC now owns 15,000 shares of the company's stock valued at $62,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in Precision BioSciences during the 3rd quarter valued at approximately $72,000. 37.99% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Precision BioSciences in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $60.00.
Read Our Latest Report on Precision BioSciences
Precision BioSciences Company Profile
(
Get Free Report)
Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company's pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.
Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
